<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="115863">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01739868</url>
  </required_header>
  <id_info>
    <org_study_id>09/9-A</org_study_id>
    <nct_id>NCT01739868</nct_id>
  </id_info>
  <brief_title>Screening and Understanding of the Pre-diabetes: DECODIAB</brief_title>
  <acronym>DECODIAB</acronym>
  <official_title>Screening and Understanding of the Pre-diabetes: DECODIAB</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to understand the pathophysiological mechanisms involved
      in switching from pre-diabetes to type 2 diabetes and to identify new biomarkers of type 2
      diabetes risk in the population of patients with pre-diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment</study_design>
  <primary_outcome>
    <measure>To identify new biomarkers</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The main objective of the study is to understand the pathophysiological mechanisms involved in switching from pre-diabetes to type 2 diabetes and to identify new biomarkers of type 2 diabetes risk in the population of patients with pre-diabetes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To identify new therapeutic targets</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To identify new therapeutic targets for the prevention of the appearance of the diabetes in the population of patients with pre-diabetes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To connect identified biomarkers with the degree of insulinoresistance</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To connect identified biomarkers with the degree of insulinoresistance (HOMA-R) and with β pancreatic function (IOG) in the population of patients with pre-diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with high Diabetes Risk Score and pre-diabetes</measure>
    <safety_issue>No</safety_issue>
    <description>To evaluate the interest of the Diabetes Risk Score in identifying subjects with pre-diabetes in the French population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with others cardiovascular risk factors</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the prevalence of others cardiovascular risk factors associated with pre-diabetes: dyslipidemia, hypertension, metabolic liver disease</description>
  </secondary_outcome>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Pre-diabetes</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biopsies of muscular and fat tissue</intervention_name>
    <description>3 half days of metabolic exploration including blood sample, urinary taking, OGTT (oral glucose tolerance test), biopsies of muscular and fat tissue:
1 visit the first year (inclusion visit)
1 visit at the end of 5 years of follow-up or in the appearance of type 2 diabetes
1 intermediary visit (in 3 years) or activated by the following conditions:
Escalation of the glycemia (increase of 0.1g / l of the glycemia and/or 0.3 % of the HbA1c)
Normalization of the glycemia (fasting blood glucose &lt; 1 g/l)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (≥18 years)

          -  Subjects with diabetes risk score ≥ 12 or with impaired fasting glucose: blood
             glucose ≥ 1.10 g/l and &lt; 1 .26 g/L

          -  And with impaired fasting glucose : blood glucose ≥ 1.10 g/l and &lt; 1 .26 g/L ; or
             blood glucose ≥ 1g/l and &lt; 1,1 g/L WITH HbA1C ≥ 6,5%

          -  Signed informed consent

          -  Subjects affiliated with an appropriate social security system

        Exclusion Criteria:

          -  Fasting glycemia ≥ 1.26 g/l

          -  Fasting glycemia ≤ 1.10 g/l AND HbA1C &lt; 6,5%

          -  Fasting glycemia &lt; 1 g/l

          -  Subjects previously treated with oral anti-diabetic: metformin, glitazones,
             inhibitors of α-glucosidase, sulfonylurea, repaglinide, inhibitors of DPP-IV.

          -  Subjects previously treated with insulin, except  gestational diabetes

          -  Severe coagulation disorders

          -  Thrombocytopenia &lt; 100 000/mm 3

          -  Severe psychiatric disorders

          -  Severe renal insufficiency (creatinine clearance &lt; 30 ml/min)

          -  Severe hepatic insufficiency

          -  Alcohol abuse (&gt; 30g/j)

          -  Contra-indication in the realization of the local anesthetic

          -  Subject unable to follow the study during the 5 years of follow-up

          -  Subject exclusion period in a previous study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertrand CARIOU, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bertrand CARIOU, Pr</last_name>
    <phone>02 53 48 27 10</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand CARIOU, Pr</last_name>
      <phone>02 53 48 27 10</phone>
    </contact>
    <investigator>
      <last_name>Bertrand CARIOU, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 28, 2012</lastchanged_date>
  <firstreceived_date>November 23, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pre-diabetes</keyword>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Diabetes risk score</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
